- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Case reports of patients with ALK-positive NSCLC and brain metastases2023 | First Faculty of Medicine
- Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectini2020 | Publication without faculty affiliation
- Alecensa - a new hope for patients with ALK positive non-small cell lung cancer2018 | Second Faculty of Medicine
- Patient with NSCLC and brain metastases and positive reassortment ALK treated with alectinib - case report2020 | Publication without faculty affiliation
- Ceritinib - a new hope for patients with ALK-positive translocation of non-small-cell lung cancers +12015 | Faculty of Medicine in Pilsen
- Long time successful treatment of a young patient suffering from advanced ALK rearreged lung adenocarcinoma2018 | Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance2019 | Faculty of Pharmacy in Hradec Králové
- Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas2019 | Second Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2020 | First Faculty of Medicine
- Advanced lung cancer as chronic disease2015 | Faculty of Medicine in Pilsen
- Profile of the drug Xalkori2014 | Faculty of Medicine in Pilsen
- New alternatives and approaches in the treatment of advanced non-small cell lung cancer2015 | Faculty of Medicine in Pilsen
- Targeted treatment of bronchogenic carcinoma2020 | First Faculty of Medicine
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Lorlatinib in the treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- Inflammatory myofibroblastic tumor of the uterus - case report2019 | Faculty of Medicine in Pilsen
- Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis2020 | Publication without faculty affiliation
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)2021 | Second Faculty of Medicine
